Ripafest Eye Drops contain Ripasudil (0.4% w/v), a ROCK inhibitor ophthalmic solution used for reducing elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension, helping to prevent optic nerve damage and preserve vision.
Ripasudil works by increasing aqueous humor outflow through the trabecular meshwork, effectively lowering IOP. Its precise formulation ensures consistent pressure reduction with minimal side effects, supporting long-term ocular health.
Clinically, Ripafest Eye Drops provide once or twice daily dosing convenience, improving patient adherence and delivering reliable therapeutic outcomes. Ophthalmologists prefer Ripasudil for its proven efficacy and safety in IOP management.
From a business perspective, Ripafest Eye Drops strengthen the anti-glaucoma ophthalmic portfolio, offering high prescription demand, repeat orders, and profitable PCD franchise opportunities. Its clinical trust and prescriber confidence make it a valuable addition for distributors and stockists across India.